Familial Mediterranean Fever (FMF), Female and Male Fertility: Literature Review
https://doi.org/10.25557/2073-7998.2021.01.3-11
Abstract
Familial Mediterranean fever (FMF) is a monogenic inherited autoinflammatory disease characterized by recurrent episodes (attacks) of fever, serositis of different localization, arthritis, erysipelaslike rashes. Eastern Mediterranean persons (especially Turks, Armenians, Arabs, Sephardic Jews) are most frequently affected. Nowadays the disease is registered throughout the world because of migration processes. Potential complications of FMF (fibrosis and amyloidosis) and their treatment with colchicine may affect the reproductive system either by salpinx obstruction causing mechanical infertility, or by excessive formation of defective sperm and oocytes, either due to ovarian /testicular insufficiency. Amyloidosis can lead to female and male infertility with amyloid preponderance in the ovaries and testicles. Colchicine rarely induces oligo/ azoospermia in men. In women, disovulation and peritoneal adhesion were the main causes of infertility in the past. In recent years, the fertility situation has improved considerably due to the use of colchicine. The review summarizes current information on the relationship between female and male fertility with FMF and colchicine; modern approaches to restoring reproductive function in infertility are outlined. The focus is on the aspects of the safety of therapy, the main provisions of which are presented in the clinical recommendations for treatment of the FMF of the European Anti-Rheumatic League (EULAR, 2016).
About the Author
P. O. Sotskiy
Center of Medical Genetics and Primary Health Care
Russian Federation
Russian Federation
References
1. Siegal S. Benign paroxysmal peritonitis. Ann Intern Med. 1945;23(1):1
2. Ben-Chetrit E., Touitou I. Familial mediterranean Fever in the world. Arthritis Rheum. 2009;61(10):1447-1453.
3. Ben-Chetrit E., Levy M. Familial Mediterranean fever. Lancet 1998; 351:659-664. doi:10.1016/S0140-6736(97)09408-7
4. Sohar E., Gafni J., Pras M., Heller H. Familial Mediterranean fever: a survey of 470 cases and review of the literature. Am J Med 1967; 43:227-253. doi:10.1016/0002-9343(67)90167-2
5. Goldfinger S.E. Colchicine for familial Mediterranean fever. N Eng J Med. 1972;287:1302. doi:10.1056/NEJM197212212872514
6. Taylor E. W. The mechanism of colchicine inhibition of mitosis. Kinetics of Inhibition and the Binding of H3-Colchicine. J Cell Biol.1965;25(1):145-160. doi:10.1083/jcb.25.1.145
7. Ehrenfeld E.N., Polishuk W.Z. Gynecological aspects of recurrent polyserositis. Isr J Med Sci. 1970; 6:9-13.
8. Mamou H. Periodic Disease and Endocrine Disorders. Semin Hop Paris.1970;46:2027-2029.
9. Ismajovich B., Zemer D., Revach M. et al. The causes of infertility in females with familial editerranean fever. Fertil Steril.1973;24:844-847. doi:10.1016/s0015-0282(16)40030-0
10. Ben-Chetrit E., Ben-Chetrit A., Berkun Y., Ben-Chetrit E. Pregnancy outcomes in women with familial Mediterranean fever receiving colchicine: is amniocentesis justified? Arthritis Care Res.2010; 62(2):143-148. doi:10.1002/acr.20061
11. Yanmaz M.N., Özcan A.J., Savan K. The impact of familial Mediterranean fever on reproductive system. Clin Rheumatol. 2014;33(10):1385-1388. doi:10.1007/s10067-014-2709-9
12. Sarı İ., Birlik M., Kasifoğlu T. Familial Mediterranean fever: An updated review. Eur J Rheumatol. 2014;1(1):21-33. doi:10.5152/eurjrheum.2014.006
13. Dotters-Katz S., Kuller J., Price T. The impact of familial Mediterranean fever on women’s health. Obstet Gynecol Surv. 2012;67(6):357-364. doi:10.1097/OGX.0b013e318259ed3a
14. Indraratna P., Virk S., Gurram D., Day R. Use of colchicine in pregnancy: A systematic review and meta-analysis. Rheumatology (Oxford) 2018; 57(2):382-387. doi:10.1093/rheumatology/kex353.
15. Granat M., Tur-Kaspa I., Zylber-Katz E., Schenker J.G. Reduction of peritoneal adhesion formation by colchicine: a comparative study in the rat. Fertil Steril 1983; 40:369-372. doi:10.1016/s0015-0282(16)47302-4.
16. Ben-Chetrit E., Levy M. Reproductive system in familial Mediterranean fever: an overview. Ann Rheum Dis 2003; 62:916-919. doi: 10.1136/ard.62.10.916.
17. Ben-Chetrit E. Clinical manifestations and diagnosis of familial Mediterranean fever. Available at: https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-mediterranean-fever/print
18. French FMFC. A candidate gene for Familial Mediterranean Fever. Nat Genet 1997;17:25-31. doi:10.1038/ng0997-25.
19. The International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 1997; 90:797-807. doi: 10.1016/s0092-8674(00)80539-5.
20. de Menthière С.S., Terrière S., Pugnère D., Ruiz M., Demaille J., Touitou I. INFEVERS: the Registry for FMF and hereditary inflammatory disorders mutations/ Nucleic Acids Research 2003; 31(1): 282-285. https://doi.org/10.1093/nar/gkg031
21. Ozdogan H., Ugurlu S. Familial Mediterranean Fever. Presse Med. 2019;48(1):61-76. doi:10.1016/j.lpm.2018.08.014.
22. Touitou I. The spectrum of Familial Mediterranean Fever (FMF) mutations. Eur J Hum Gen 2001;9(7):473-483. doi:10.1038/sj.ejhg.5200658.
23. Shinar Y., Obici L., Aksentijevich I., Sarkisian T. Guidelines for the genetic diagnosis of hereditary recurrent fevers. Ann Rheum Dis. 2012;71(10):1599-1605. doi: 10.1136/annrheumdis-2011-201271
24. Gershoni-Baruch R., Вrik R., Shinawi M., Livneh A. The differential contribution of MEFV mutant alleles to the clinical profile of Familial Mediterranean Fever. Eur J Hum Genet 2002;10(2):145-149. doi:10.1038/sj.ejhg.5200776.
25. Mijatovic V., Hompes P.G., Wouters M.G. Familial Mediterranean fever and its implications for fertility and pregnancy. Eur J Obstet Gynecol Reprod Biol 2003.10;108(2):171-176. doi:10.1016/s0301-2115(02)00417-7.
26. Cerquaglia C., Verrecchia E., Fonnesu C. et al. Female reproductive dysfunction in familial Mediterranean fever patients with and without colchicine treatment. Clin Exp Rheumatol 2010;28:S101.
27. Ofir D., Levy A., Wiznitzer A. et al. Familial Mediterranean fever during pregnancy: an independent risk factor for preterm delivery. Eur J Obstet Gynecol Reprod Biol 2008; 141:115-118. doi:10.1016/j.ejogrb.2008.07.025.
28. Golden R.L., Weigers E.W., Meagher J.G. Periodic fever and menses. Am J Obstet Gynecol 1973; 117:855-856.
29. Ben-Chetrit E& Ben-Chetrit A. Familial Mediterranean fever and menstruation. BJOG: an international journal of obstetrics and gynaecology. 2001;108:403-407. doi:10.1111/j.1471-0528.2001.00083.x.
30. Koh K.K., Bui M.N., Mincemoyer R., Cannon R.O. 3rd. Effects of hormone therapy on inflammatory cell adhesion molecules in postmenopausal healthy women. Am J Cardiol 1997;80:1505-1507.
31. Chaudoreille M.M., Peyrot V., Braquer D. et al. Qualitative study of the interaction mechanism of estrogenic drugs with tubulin.… Biochem Pharmacol 1991March 1;41(5):685-693.
32. Levy M., Yaffe C. Testicular function in patients with familial Mediterranean fever on long-term colchicine treatment. Fertil Steril 1978; 29:667-668.doi:10.1016/s0015-0282(16)43342-x.
33. Cronstein B.N., Molad Y., Reibman J. et al. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest 1995; 96:994-1002. doi:10.1172/JCI118147.
34. Ben-Chetrit E., Levy M. Colchicine update 1998. Semin Arthritis Rheum 1998;28:48-59. doi:10.1016/s0049-0172(98)80028-0.
35. Ehrenfeld M., Brzezinski A., Levy M., Eliakim M. Fertility and obstetric history in patients with familial Mediterranean fever on long term colchicines therapy. Br J Obstet Gynaecol 1987; 94:1186-1191. doi:10.1111/j.1471-0528. 1987. Tb 02320.x.
36. Dor J., Homburg R., Rabau E. An evaluation of etiologic factors and therapies in 665 infertile couples. Fertil Steril 1977;28:718-722.
37. Uzunaslan D., Saygin C., Hatemi G. et al. No appreciable decrease in fertility in Behçet’s syndrome. Rheumatology (Oxford) 2014;53(5):828-833. doi:10.1093/rheumatology/ket436.
38. Zadeh N., Getzug T., Grody W.W. Diagnosis and management of familial Mediterranean fever: Integrating medical genetics in a dedicated interdisciplinary clinic. Genet Med 2011;13(3):263-269. doi:10.1097/GIM.0b013e31820e27b1.
39. Haimov-Kochman R., Prus D., Ben-Chetrit E. Azoospermia due to testicular amyloidosis in a patient with familial Mediterranean fever. Hum Reprod 2001;16:1218-1220. doi:10.1093/humrep/16.6.1218.
40. Shepard T.H. Catalog of teratogenic agents, 6th ed. Baltimore, MD: Johns Hopkins University Press; 1989:164-166.
41. Merlin H.E. Azoospermia caused by colchicine - a case report. Fertil Steril 1972; 23:180-181. doi:10.1016/s0015-0282(16)38823-9.
42. Yu T.F., Gutman A.B. Efficacy of colchicine prophylaxis in gout. Ann Int Med 1961;55:179-192. doi:10.7326/0003-4819-55-2-179.
43. Bremner W.J., Plausen C.A. Colchicine and testicular function in man. N Eng J Med 1976; 294:1384-1385. doi:10.1056/NEJM197606172942508.
44. Sarica K., Suzer O., Gurler A. et al. Urological evaluation of Behcet patients and the effect of colchicine on fertility. Eur J Urol 1995; 22:39-42. doi:10.1159/000475121.
45. Ben-Chetrit E., Backenroth R., Haimov-Kochman R., Pizov G. Azoospermia in familial Mediterranean fever patients: the role of colchicines and amyloidosis. Ann Rheum Dis 1998; 57:259-260. doi:10.1136/ard.57.4.259
46. Ben-Chetrit A., Ben-Chetrit E., Nitzan R., Ron M. Colchicine inhibits human spermatozoal motility in-vitro. Inter J Fertil 1993;88:301-304.
47. Zemer D., Pras M., Shemer Y. Daily prophylactic colchicine in familial Mediterranean fever. In: Amyloid and Amyloidosis. Proceedings of the 3rd International Symposium on Amyloidosis. ExerptaMedica. Amsterdam-Oxford-Prinston. 1980:580-583.
48. Ben-Chetrit E., Berkun Y., Ben-Chetrit E., Ben-Chetrit A. The outcome of pregnancy in the wives of men with familial mediterranean fever treated with colchicine. Semin Arthritis Rheum 2004 Oct;34(2):549-552. doi:10.1016/j.semarthrit.2004.07.004.
49. Ugurlu S., Seyahi E., Hatemi G. et al. Canakinumab Therapy in Patients with Familial Mediterranean Fever. Arthritis Rheumatol 2015;67:362-363
50. Youngstein T., Hoffman P., Gul A. et al. International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors. Rheumatology 2017;456:2102-2108. doi:10.1093/rheumatology/ kex305.
51. Yilmaz N.K., Kara M., Kaba M. et al. Effect of Familial Mediterranean Fever on IVF outcome: A Retrospective Case Series. Acta Clin Croat 2016;55:254-258. doi:10.20471/acc.2016.55.02.11.
52. Ozgur K., Bulut H., Berkkanoglu M. et al. Colchicine treatment for FMF does not affect IVF outcome. Fertility and Sterility 2013;100(3):S507. doi:https://doi.org/10.1016/j.fertnstert. 2013.07.205
53. Diav-Citrin O., Shechtman S., Schwartz V. et al. Pregnancy outcome after in utero exposure to colchicine. Am J Obstet Gynecol. 2010; 203:144. doi:10.1016/j.ajog.2010.02.063.
54. Oner G., Muderris I.I. Assessment of ovarian reserve based on hormonal parameters, ovarian volume, and antral follicle count in women with familial Mediterranean fever. Eur J Obstet Gynecol Reprod Biol 2013. Oct;170(2):449-451. doi:10.1016/j.ejogrb.2013.07.023.
55. Ozen S., Demirkaya E., Erer B. et al. EULAR recommendations for the management of familial Mediterranean fever. Annals of the Rheumatic Diseases 2016;75:644-651. doi:10.1136/ annrheumdis-2015-208690.
Review
For citations:
Sotskiy P.O. Familial Mediterranean Fever (FMF), Female and Male Fertility: Literature Review. Medical Genetics. 2021;20(1):3-11. (In Russ.) https://doi.org/10.25557/2073-7998.2021.01.3-11
Views:
825
Email this article 